WebMay 25, 2024 · Carboplatin is preferred over cisplatin in the extensive stage disease because of its favorable toxicity profile. Data comparing the efficacy of carboplatin with cisplatin in the metastatic setting are limited. Methods: Data from the National VA Cancer Cube database were compiled. WebWe investigated the activity and safety of first-line GEMOX compared with gemcitabine–carboplatin (GCb) in cisplatin-ineligible patients with advanced UCC. Methods: Treatment-naive, cisplatin-ineligible patients with advanced UCC were randomly assigned to GEMOX (gemcitabine 1000 mg/m 2 , oxaliplatin 100 mg/m 2 on day 1 [D1] …
Cisplatin vs. carboplatin-based chemoradiotherapy in patients ... - PubMed
WebDec 7, 2024 · Therefore, carboplatin has been indicated as a reasonable substitute for cisplatin in ES-SCLC [ 7 ]. Recently, a meta-analysis of 663 individual patient data from … WebCisplatin Versus Carboplatin. Carboplatin is another platinum derivate with a tenfold longer half-life than cisplatin. Due to structural differences from cisplatin, it exhibits lower reactivity and slower DNA binding kinetics in vitro. In clinical studies, the nonhematologic tolerability of carboplatin is superior to that of cisplatin, making ... sims 4 star tights
cisplatin vs carboplatin — Cancer Survivors Network
WebMar 30, 2024 · The ubiquitin-proteasome system plays an important role in acquiring resistance to rituximab and chemotherapy agents in B-cell lymphoma. 9, 10 Carfilzomib (CFZ, PR-171) is a potent, tetrapeptide ketoepoxide–based inhibitor specific for the chymotrypsin-like active site of the 20S proteasome. It was first approved for the … WebDec 1, 2024 · Methods. In this open-label, randomized, phase III study, newly diagnosed patients with advanced NSCLC were initially randomized (R1, 1:1) to receive first-line treatment with cisplatin 75 mg/m 2 plus docetaxel 75 mg/m 2 (DC75) or 60 mg/m 2 (DC60) for up to 4 cycles. Patients without progression were further randomized (R2, 1:2) to best … WebDec 7, 2024 · Extensive-stage small cell lung cancer (ES-SCLC) is an aggressive disease with poor survival, and platinum-etoposide chemotherapy is indicated as the mainstay of treatment. In this study, we compared the efficacy and safety between the cisplatin plus etoposide (EP) and carboplatin plus etoposide (EC) regimens. A total of 1305 patients … rcht duty of candour policy